GlassScriptPhysician profile
Skye N Deberry
NPI 1710943584
$4,776.96
in general payments reported to CMS, 2019-2025
44 companies · $853 in 2025
The $853 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $278 · 2022: $215 · 2023: $1,173 · 2024: $1,140 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,165.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $636.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $548.55 | 2022-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $501.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $306.14 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $303.06 | 2019-2024 | |
| Exact Sciences Corporation | $167.14 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $164.10 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.74 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $143.91 | 2023-2025 | |
| Dexcom, INC. | $124.26 | 2023-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $122.34 | 2022-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $117.39 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Idorsia Pharmaceuticals US INC | $108.24 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $103.61 | 2019-2024 | Spravato, Xarelto |
| Corium, LLC | $100.45 | 2023 | Azstarys |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skye Deberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.